Nihon Kohden Corporation
【Nihon Kohden】Full-year Financial Results for 2026｜Sales ¥235 billion (YoY +4.3%)
Nihon Kohden achieved sales of ¥235 billion (YoY +4.3%) and net income of ¥14.5 billion (up 2.9%) for the fiscal year ending March 2026. Overseas operations performed well, while domestic sales saw a slight decline. The forecast for the next period projects sales of ¥232.5 billion.
Key Figures
- Net Sales: ¥235,099 million (YoY +4.3%)
- Net income attributable to owners of parent: ¥14,513 million (+2.9%)
- Next period sales forecast: ¥232,500 million (YoY -1.1%)
AI要約
Performance Overview
Nihon Kohden recorded sales of ¥235 billion (YoY +4.3%) and net income of ¥14.5 billion (+2.9%) for the fiscal year ending March 2026. While overseas business remained robust, domestic sales declined slightly, impacting profit. Operating income decreased, but ordinary income and net income remained solid. The outlook for the next period forecasts sales of ¥232.5 billion (YoY -1.1%) and net income of ¥15 billion, with continued focus on overseas expansion and profitability improvement.
Future Outlook and Strategy
The company aims to enhance growth, profitability, and capital efficiency under the medium-term management plan 'BEACON 2030 Phase II.' Domestic efforts include offsetting declines due to the end of Abbott product sales by expanding proprietary products and digital health solutions. Overseas, demand for medical devices remains strong in North America, and local production in India is planned. The company strives to improve profit margins and reduce costs, targeting sales of ¥255.6 billion and net income of ¥2.5 billion in FY2027.
Nihon Kohden Corporation
Company overview · Stock price · Financial data · All IR
